Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a BetZacks Investment Research • 03/04/25
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate UpdatesBusiness Wire • 02/27/25
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?Zacks Investment Research • 02/24/25
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)Zacks Investment Research • 02/24/25
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to TradeZacks Investment Research • 01/28/25
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025Business Wire • 01/28/25
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)Business Wire • 01/23/25
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of SchizophreniaBusiness Wire • 01/17/25
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 01/15/25
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and SingaporeBusiness Wire • 01/10/25
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and SingaporeBusiness Wire • 01/10/25
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug ConjugateBusiness Wire • 01/09/25
Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/24/24
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic CancerBusiness Wire • 12/02/24
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug ListBusiness Wire • 11/28/24
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)Business Wire • 11/21/24
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary SharesBusiness Wire • 11/18/24
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/12/24